Fibrinolytic Activity and the Effects of Beta-Pyridylcarbinol (Ronicol) in Patients with Arteriosclerosis Obliterans

Summary

Twenty-one patients with arteriosclerosis obliterans of lower extremities were treated with beta-pyridylcarbinol (Ronicol) for five weeks. The long-term therapy with beta-pyridylcarbinol did not influence platelet aggregability. Activation of the fibrinolytic system was observed. This fibrinolytic effect of Ronicol was abolished in patients treated with aspirin. In most cases a slight clinical improvement was seen, manifested by elongation of pain-free walking distance and increased blood flow in affected limbs. It is concluded that the therapeutic effect of Ronicol in humans may be partly mediated by the release of endogenous prostacyclin.

Keywords

Arteriosclerosis obliterans - Platelet aggregation - Fibrinolysis - Aspirin

• References

• 1 Mund-Hoym WD. Behandlung chronisch arterieller Angiopathien mit Beta-pyridylcarbinol. Ars Medici (Liestal) 1979; 69: 474-484
• 2 Laursen B, Gorman J. Studies on fibrinolytic activity in normal persons and in patients with atherosclerotic vascular disease after physical activity and injections of nicotinic acid. Angiology 1970; 21: 486-492
• 3 Stuart SE. Long acting form of the peripheral vasodilatory nicotinyl alcohol: double-blind evaluation. J Am Geriatr Soc 1976; 15: 780-785
• 4 Zöllner N, Gudenzi M. Behandlung der Hypercholesterinämie mit Beta-pyridylcarbinol. Med Klinik 1966; 51: 2036-2040
• 5 Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic add on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor. Med Biol 1979; 57: 114-117
• 6 Dembińska-Kieć A, Korbut R, Bieron K, Kostka-Trgöka E, Gryg-lewski R. Beta-pyridylcarbinol (Ronicol®) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharm Res Commun 1983; 15: 377-385
• 7 Whitney RJ. The measurement of volume changes in human limbs. J Physiol 1953; 121: 1-27
• 8 Splawiński J, Wojtaszek B, Marcinkiewicz E. Bioassay of thrombo-xane A₂by contraction of guinea pig parenchyma lung strip. Thromb Res 1981; 21: 35-44
• 9 Kaulla von KN, Schultz RL. Methods for evaluation of human fibrinolysis. Am J Clin Path 1958; 29: 104-112
• 10 Wheithman KU, Granzer E. Stimulation of anti-aggregatory activity from rat aorta by hypolipidemic drugs. Artery 1980; 8: 475-481
• 11 Szczeklik A, Gryglewski R. Treatment of vascular disease with prostacyclin. In: Clinical Pharmacology of Prostacyclin. Lewis PJ, O’Grady J. (Eds) Raven Press; New York: 1981. pp 159-168
• 12 Dembińska-Kieć A, Kostka-Trąbka E, Żmuda A, Byrska-Danek A, Bieroń K, Grodzińska L, Kȩdzior A, Żelazny T. Effect of prostacyclin on platelet and fibrinolytic activity in patients with arteriosclerosis obliterans. Pharm Res Commun 1982; 14: 485-498
• 13 Vincent JE, Zijstra FJ. Nicotinic add inhibits thromboxane synthesis in platelets. Prostaglandins 1978; 15: 628-636